Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - betaxolol hydrochloride - eye drops - 5mg/1ml

Malta - Englisch - Malta Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - betaxolol hydrochloride - eye drops, suspension - betaxolol hydrochloride 2.5 mg/ml - ophthalmologicals

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml (equivalent: betaxolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: purified water; disodium edetate; sodium chloride; hydrochloric acid; benzalkonium chloride; sodium hydroxide - indications as at 23 march 1999: betoquin eye drops 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoquin eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Japan - Englisch - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - betaxolol hydrochloride - white tablet with split line, diameter: 7.1 mm, thickness: 3.2 mm

Japan - Englisch - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - betaxolol hydrochloride - white tablet with split line, diameter: 5.6 mm, thickness: 2.5mm

Japan - Englisch - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - betaxolol hydrochloride - white tablet, diameter: 7.1 mm, thickness: 3.3 mm

Japan - Englisch - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - betaxolol hydrochloride - white tablet, diameter: 6.1 mm, thickness: 3.2 mm

Belgien - Englisch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novartis pharma sa-nv - betaxolol hydrochloride 5,6 mg/ml - eq. betaxolol 5 mg/ml - eye drops, solution - 5 mg/ml - betaxolol hydrochloride 5.6 mg/ml - betaxolol

Belgien - Englisch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novartis pharma sa-nv - betaxolol hydrochloride 2,8 mg/g - eq. betaxolol 2,5 mg/g - eye drops, suspension - 2,5 mg/ml - betaxolol hydrochloride 2.8 mg/g - betaxolol